Antibiotic therapy for inducible AmpC β-lactamase-producing Gram-negative bacilli: What are the alternatives to carbapenems, quinolones and aminoglycosides?

International Journal of Antimicrobial Agents

Volumn 40, Issue 4, 2012, Pages 297-305

  Harris, P N A ^a   Ferguson, J K ^a,b,c  

^a JOHN HUNTER HOSPITAL   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c UNIVERSITY OF NEW ENGLAND   (Australia)

Author keywords

Cefepime; Cefotaxime; Ceftriaxone; Citrobacter; Enterobacter; Piperacillin tazobactam; Serratia; Trimethoprim sulfamethoxazole

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOPENICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE AMPC; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; METRONIDAZOLE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UREIDOPENICILLIN DERIVATIVE;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ASEPTIC MENINGITIS; BACTEREMIA; BACTERIAL MENINGITIS; BLOOD TOXICITY; CITROBACTER FREUNDII; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG TISSUE LEVEL; DRUG TREATMENT FAILURE; ENTEROBACTER; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE INFECTION; EPILEPTIC STATE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; GRAM NEGATIVE SEPSIS; HEMATOLOGIC DISEASE; HUMAN; HYPERKALEMIA; HYPOGLYCEMIA; INFECTION; KIDNEY DYSFUNCTION; LIVER FAILURE; LOWER RESPIRATORY TRACT INFECTION; MINIMUM INHIBITORY CONCENTRATION; MORGANELLA MORGANII; MORTALITY; MULTIDRUG RESISTANCE; NAUSEA; NEUROTOXICITY; NONHUMAN; PERITONITIS; PNEUMONIA; PRIORITY JOURNAL; PROVIDENCIA; PSYCHOSIS; REVIEW; RHABDOMYOLYSIS; SEPSIS; SERRATIA INFECTION; SERRATIA MARCESCENS; SIDE EFFECT; SKIN INFECTION; URINARY TRACT INFECTION; VOMITING;

EID: 84866045512     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2012.06.004     Document Type: Short Survey

References (139)

1. J.W. Chow, M.J. Fine, D.M. Shlaes, J.P. Quinn, D.C. Hooper, and M.P. Johnson Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy Ann Intern Med 115 1991 585 590
2. R.P. Ambler The structure of β-lactamases Philos Trans R Soc Lond B Biol Sci 289 1980 321 331
3. K. Bush, G.A. Jacoby, and A.A. Medeiros A functional classification scheme for β-lactamases and its correlation with molecular structure Antimicrob Agents Chemother 39 1995 1211 1233
4. W.E. Sanders, and C.C. Sanders Enterobacter spp.: pathogens poised to flourish at the turn of the century Clin Microbiol Rev 10 1997 220 241
5. C.C. Sanders, and W.E. Sanders Jr. β-Lactam resistance in Gram-negative bacteria: global trends and clinical impact Clin Infect Dis 15 1992 824 839
6. D.M. Livermore β-Lactamases in laboratory and clinical resistance Clin Microbiol Rev 8 1995 557 584
7. N. Liassine, S. Madec, B. Ninet, C. Metral, M. Fouchereau-Peron, and R. Labia Postneurosurgical meningitis due to Proteus penneri with selection of a ceftriaxone-resistant isolate: analysis of chromosomal class A β-lactamase HugA and its LysR-type regulatory protein HugR Antimicrob Agents Chemother 46 2002 216 219
8. M.B. Avison, S. Underwood, A. Okazaki, T.R. Walsh, and P.M. Bennett Analysis of AmpC β-lactamase expression and sequence in biochemically atypical ceftazidime-resistant Enterobacteriaceae from paediatric patients J Antimicrob Chemother 53 2004 584 591
9. T. Naas, D. Aubert, N. Fortineau, and P. Nordmann Cloning and sequencing of the β-lactamase gene and surrounding DNA sequences of Citrobacter braakii, Citrobacter murliniae, Citrobacter werkmanii, Escherichia fergusonii and Enterobacter cancerogenus FEMS Microbiol Lett 215 2002 81 87
10. G.A. Jacoby AmpC β-lactamases Clin Microbiol Rev 22 2009 161 182
11. S. Petrella, M. Renard, N. Ziental-Gelus, D. Clermont, V. Jarlier, and W. Sougakoff Characterization of the chromosomal class A β-lactamase CKO from Citrobacter koseri FEMS Microbiol Lett 254 2006 285 292
12. J.D. Pitout, E.S. Moland, C.C. Sanders, K.S. Thomson, and S.R. Fitzsimmons β-Lactamases and detection of β-lactam resistance in Enterobacter spp. Antimicrob Agents Chemother 41 1997 35 39
13. I. Stock, and B. Wiedemann Natural antibiotic susceptibility of Enterobacter amnigenus, Enterobacter cancerogenus, Enterobacter gergoviae and Enterobacter sakazakii strains Clin Microbiol Infect 8 2002 564 578
14. I. Stock, S. Burak, K.J. Sherwood, T. Gruger, and B. Wiedemann Natural antimicrobial susceptibilities of strains of 'unusual' Serratia species: S. ficaria, S. fonticola, S. odorifera, S. plymuthica and S. rubidaea J Antimicrob Chemother 51 2003 865 885
15. J.M. Janda, and S.L. Abbott The genus Aeromonas: taxonomy, pathogenicity, and infection Clin Microbiol Rev 23 2010 35 73
16. W.C. Ko, H.C. Lee, Y.C. Chuang, C.C. Liu, and J.J. Wu Clinical features and therapeutic implications of 104 episodes of monomicrobial Aeromonas bacteraemia J Infect 40 2000 267 273
17. V. Miriagou, L.S. Tzouvelekis, L. Villa, E. Lebessi, A.C. Vatopoulos, and A. Carattoli CMY-13, a novel inducible cephalosporinase encoded by an Escherichia coli plasmid Antimicrob Agents Chemother 48 2004 3172 3174
18. K.S. Thomson Extended-spectrum-β-lactamase, AmpC, and carbapenemase issues J Clin Microbiol 48 2010 1019 1025
19. P. Biller, B. Shank, L. Lind, M. Brennan, L. Tkatch, and G. Killgore Moxifloxacin therapy as a risk factor for Clostridium difficile-associated disease during an outbreak: attempts to control a new epidemic strain Infect Control Hosp Epidemiol 28 2007 198 201
20. R. Gaynes, D. Rimland, E. Killum, H.K. Lowery, T.M. Johnson 2nd, and G. Killgore Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use Clin Infect Dis 38 2004 640 645
21. I. Willemsen, B. Cooper, C. van Buitenen, M. Winters, G. Andriesse, and J. Kluytmans Improving quinolone use in hospitals by using a bundle of interventions in an interrupted time series analysis Antimicrob Agents Chemother 54 2010 3763 3769
22. B.S. Gottesman, Y. Carmeli, P. Shitrit, and M. Chowers Impact of quinolone restriction on resistance patterns of Escherichia coli isolated from urine by culture in a community setting Clin Infect Dis 49 2009 869 875
23. Antibiotic Expert Group Therapeutic guidelines: antibiotic, version 14 2010 Therapeutic Guidelines Ltd. Melbourne, Australia
24. A.L. Pakyz, Oinonen, and R.E. Polk Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenem-resistant Pseudomonas aeruginosa Antimicrob Agents Chemother 53 2009 1983 1986
25. K.S. Kaye, S. Cosgrove, A. Harris, G.M. Eliopoulos, and Y. Carmeli Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp. Antimicrob Agents Chemother 45 2001 2628 2630
26. S.H. Choi, J.E. Lee, S.J. Park, S.H. Choi, S.O. Lee, and J.Y. Jeong Emergence of antibiotic resistance during therapy for infections caused by Enterobacteriaceae producing AmpC β-lactamase: implications for antibiotic use Antimicrob Agents Chemother 52 2008 995 1000
27. S.E. Cosgrove, K.S. Kaye, G.M. Eliopoulous, and Y. Carmeli Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species Arch Intern Med 162 2002 185 190
28. E.N. Deal, S.T. Micek, D.J. Ritchie, R.M. Reichley, W.M. Dunne Jr., and M.H. Kollef Predictors of in-hospital mortality for bloodstream infections caused by Enterobacter species or Citrobacter freundii Pharmacotherapy 27 2007 191 199
29. C.I. Kang, S.H. Kim, W.B. Park, K.D. Lee, H.B. Kim, and M.D. Oh Bloodstream infections caused by Enterobacter species: predictors of 30-day mortality rate and impact of broad-spectrum cephalosporin resistance on outcome Clin Infect Dis 39 2004 812 818
30. J.D. Siebert, R.B. Thomson Jr., J.S. Tan, and L.W. Gerson Emergence of antimicrobial resistance in Gram-negative bacilli causing bacteremia during therapy Am J Clin Pathol 100 1993 47 51
31. R.J. Boyle, N. Curtis, N. Kelly, S.M. Garland, and J.R. Carapetis Clinical implications of inducible β-lactamase activity in Gram-negative bacteremia in children Pediatr Infect Dis J 21 2002 935 940
32. S.H. Choi, Y.S. Kim, J.W. Chung, T.H. Kim, E.J. Choo, and M.N. Kim Serratia bacteremia in a large university hospital: trends in antibiotic resistance during 10 years and implications for antibiotic use Infect Control Hosp Epidemiol 23 2002 740 747
33. F.W. Goldstein Cephalosporinase induction and cephalosporin resistance: a longstanding misinterpretation Clin Microbiol Infect 8 2002 823 825
34. D.M. Livermore, D.F. Brown, J.P. Quinn, Y. Carmeli, D.L. Paterson, and V.L. Yu Should third-generation cephalosporins be avoided against AmpC-inducible Enterobacteriaceae? Clin Microbiol Infect 10 2004 84 85
35. Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-second informational supplement. Document M100-S22. Wayne, PA: CLSI; 2012.
36. D.L. Paterson, and R.A. Bonomo Extended-spectrum β-lactamases: a clinical update Clin Microbiol Rev 18 2005 657 686
37. J. Rodriguez-Bano, M.D. Navarro, P. Retamar, E. Picon, and A. Pascual β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts Clin Infect Dis 54 2012 167 174
38. Z.A. Qureshi, D.L. Paterson, D.L. Pakstis, J.M. Adams-Haduch, G. Sandkovsky, and E. Sordillo Risk factors and outcome of extended-spectrum β-lactamase-producing Enterobacter cloacae bloodstream infections Int J Antimicrob Agents 37 2011 26 32
39. C.C. Lee, N.Y. Lee, J.J. Yan, H.C. Lee, P.L. Chen, and C.M. Chang Bacteremia due to extended-spectrum-β-lactamase-producing Enterobacter cloacae: role of carbapenem therapy Antimicrob Agents Chemother 54 2010 3551 3556
40. H. Nikaido, W. Liu, and E.Y. Rosenberg Outer membrane permeability and β-lactamase stability of dipolar ionic cephalosporins containing methoxyimino substituents Antimicrob Agents Chemother 34 1990 337 342
41. M.C. Negri, and F. Baquero In vitro selective concentrations of cefepime and ceftazidime for AmpC β-lactamase hyperproducer Enterobacter cloacae variants Clin Microbiol Infect 5 Suppl. 1 1999 S25 S28
42. T.M. Chapuis, E. Giannoni, P.A. Majcherczyk, R. Chiolero, M.D. Schaller, and M.M. Berger Prospective monitoring of cefepime in intensive care unit adult patients Crit Care 14 2010 R51
43. J. Lipman, S.C. Wallis, and R.J. Boots Cefepime versus cefpirome: the importance of creatinine clearance Anesth Analg 97 2003 1149 1154
44. J. Lipman, S.C. Wallis, and C. Rickard Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing Antimicrob Agents Chemother 43 1999 2559 2561
45. D.H. Rhoney, V.H. Tam, D. Parker Jr., P.S. McKinnon, and W.M. Coplin Disposition of cefepime in the central nervous system of patients with external ventricular drains Pharmacotherapy 23 2003 310 314
46. T.P. Lodise Jr., D.H. Rhoney, V.H. Tam, P.S. McKinnon, and G.L. Drusano Pharmacodynamic profiling of cefepime in plasma and cerebrospinal fluid of hospitalized patients with external ventriculostomies Diagn Microbiol Infect Dis 54 2006 223 230
47. D. Breilh, E. Boselli, J.C. Bel, D. Chassard, M.C. Saux, and B. Allaouchiche Diffusion of cefepime into cancellous and cortical bone tissue J Chemother 15 2003 134 138
48. D. Breilh, M.C. Saux, C. Delaisement, A. Fratta, D. Ducint, and J.F. Velly Pharmacokinetic population study to describe cefepime lung concentrations Pulm Pharmacol Ther 14 2001 69 74
49. A. Endimiani, and D.L. Paterson Cefepime 6th ed. L.M. Grayson, S. Crowe, J. McCarthy, J. Mills, J. Mouton, R. Norrby, Kucers' the use of antibiotics vol. 1 2010 Hodder Arnold London, UK 425 441
50. J.M. Bell, and J.D. Turnidge Multicentre study of the in vitro activity of cefepime, a broad-spectrum cephalosporin, compared to other broad-spectrum agents Pathology 33 2001 53 60
51. Turnidge J, Gottlieb T, Mitchell D, Pearson J, Bell J. Gram-negative survey: 2008 antimicrobial susceptibility report. Australian Group on Antimicrobial Resistance (AGAR); 2011. http://www.agargroup.org/files/ AGAR%20GNB08%20Report%20FINAL.pdf [accessed 26.06.12].
52. Turnidge J, Gottlieb T, Mitchell D, Pearson J, Bell J. Gram-negative survey: 2009 antimicrobial susceptibility report. Australian Group on Antimicrobial Resistance (AGAR); 2011. http://www.agargroup.org/files/ AGAR%20GNB09%20Final%20Report.pdf [accessed 26.06.12].
53. S. Mushtaq, Y. Ge, and D.M. Livermore Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized β-lactamases Antimicrob Agents Chemother 48 2004 1313 1319
54. X. Bertrand, and M.J. Dowzicky Antimicrobial susceptibility among Gram-negative isolates collected from intensive care units in North America, Europe, the Asia-Pacific Rim, Latin America, the Middle East, and Africa between 2004 and 2009 as part of the Tigecycline Evaluation and Surveillance Trial Clin Ther 34 2012 124 137
55. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 1.3. EUCAST; 2011. http://www.eucast.org/clinical-breakpoints/ [accessed 20.11.11].
56. D. Barckow, and C.D. Schwigon Cefepime versus cefotaxime in the treatment of lower respiratory tract infections J Antimicrob Chemother 32 Suppl. B 1993 187 193
57. H. Kieft, A.I. Hoepelman, M. Rozenberg-Arska, J.M. Branger, J.H. Voskuil, and A.B. Geers Cefepime compared with ceftazidime as initial therapy for serious bacterial infections and sepsis syndrome Antimicrob Agents Chemother 38 1994 415 421
58. J.H. Schrank Jr., J.W. Kelly, and C.K. McAllister Randomized comparison of cefepime and ceftazidime for treatment of hospitalized patients with Gram-negative bacteremia Clin Infect Dis 20 1995 56 58
59. P.S. Barie, S.B. Vogel, E.P. Dellinger, O.D. Rotstein, J.S. Solomkin, and J.Y. Yang A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Cefepime Intra-abdominal Infection Study Group Arch Surg 132 1997 1294 1302
60. T.V. Berne, A.E. Yellin, M.D. Appleman, P.N. Heseltine, and M.A. Gill A clinical comparison of cefepime and metronidazole versus gentamicin and clindamycin in the antibiotic management of surgically treated advanced appendicitis Surg Gynecol Obstet 177 Suppl. 1993 18 22 [discussion 35-40]
61. A. Aufiero, C. Sturani, P. Zanon, A. Marruchella, G. Michetti, and E. Nicolin Cefepime versus ceftazidime in the treatment of lower respiratory tract infections J Chemother 9 1997 213 218
62. J.S. Bradley, and A. Arrieta Empiric use of cefepime in the treatment of lower respiratory tract infections in children Pediatr Infect Dis J 20 2001 343 349
63. P. Biron, C. Fuhrmann, H. Cure, P. Viens, D. Lefebvre, and A. Thyss Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study group of Infectious Diseases in Cancer) J Antimicrob Chemother 42 1998 511 518
64. Y.Y. Chuang, I.J. Hung, C.P. Yang, T.H. Jaing, T.Y. Lin, and Y.C. Huang Cefepime versus ceftazidime as empiric monotherapy for fever and neutropenia in children with cancer Pediatr Infect Dis J 21 2002 203 209
65. F.D. Wang, C.Y. Liu, H.C. Hsu, J.P. Gau, W.K. Chau, and M.L. Haung A comparative study of cefepime versus ceftazidime as empiric therapy of febrile episodes in neutropenic patients Chemotherapy 45 1999 370 379
66. W.E. Sanders Jr., J.H. Tenney, and R.E. Kessler Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species Clin Infect Dis 23 1996 454 461
67. S.V. Bhat, A.Y. Peleg, T.P. Lodise Jr., K.A. Shutt, B. Capitano, and B.A. Potoski Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by Gram-negative organisms Antimicrob Agents Chemother 51 2007 4390 4395
68. M. Paul, D. Yahav, A. Fraser, and L. Leibovici Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials J Antimicrob Chemother 57 2006 176 189
69. D. Yahav, M. Paul, A. Fraser, N. Sarid, and L. Leibovici Efficacy and safety of cefepime: a systematic review and meta-analysis Lancet Infect Dis 7 2007 338 348
70. A.G. Freifeld, and K. Sepkowitz Cefepime and death: reality to the rescue Clin Infect Dis 51 2010 390 391
71. US Food and Drug Administration. NDA 50-679 cefepime hydrochloride, statistical evaluation of mortality risk. FDA; 2008. http://www.fda.gov/ downloads/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/UCM167309.pdf [accessed 29.09.11].
72. A.C. Kalil Is cefepime safe for clinical use? A Bayesian viewpoint J Antimicrob Chemother 66 2011 1207 1209
73. H. Alpay, O. Altun, and N.K. Biyikli Cefepime-induced non-convulsive status epilepticus in a peritoneal dialysis patient Pediatr Nephrol 19 2004 445 447
74. F. Barbey, D. Bugnon, and J.P. Wauters Severe neurotoxicity of cefepime in uremic patients Ann Intern Med 135 2001 1011
75. D. Chatellier, M. Jourdain, J. Mangalaboyi, F. Ader, C. Chopin, and P. Derambure Cefepime-induced neurotoxicity: an underestimated complication of antibiotherapy in patients with acute renal failure Intensive Care Med 28 2002 214 217
76. F.J. Capparelli, M.F. Diaz, A. Hlavnika, N.A. Wainsztein, R. Leiguarda, and M.E. Del Castillo Cefepime- and cefixime-induced encephalopathy in a patient with normal renal function Neurology 65 2005 1840
77. W. Diemont, M. MacKenzie, N. Schaap, G. Goverde, H. van Heereveld, and Y. Hekster Neuropsychiatric symptoms during cefepime treatment Pharm World Sci 23 2001 36
78. J.E. Martinez-Rodriguez, F.J. Barriga, J. Santamaria, A. Iranzo, J.A. Pareja, and M. Revilla Nonconvulsive status epilepticus associated with cephalosporins in patients with renal failure Am J Med 111 2001 115 119
79. A.P. Limaye, R.K. Gautom, D. Black, and T.R. Fritsche Rapid emergence of resistance to cefepime during treatment Clin Infect Dis 25 1997 339 340
80. J. Fung-Tomc, T.J. Dougherty, F.J. DeOrio, V. Simich-Jacobson, and R.E. Kessler Activity of cefepime against ceftazidime- and cefotaxime-resistant Gram-negative bacteria and its relationship to β-lactamase levels Antimicrob Agents Chemother 33 1989 498 502
81. P. Nordmann, and H. Mammeri Extended-spectrum cephalosporinases: structure, detection and epidemiology Future Microbiol 2 2007 297 307
82. A. Endimiani, F. Perez, and R.A. Bonomo Cefepime: a reappraisal in an era of increasing antimicrobial resistance Expert Rev Anti Infect Ther 6 2008 805 824
83. S. Minami, A. Yotsuji, M. Inoue, and S. Mitsuhashi Induction of β-lactamase by various β-lactam antibiotics in Enterobacter cloacae Antimicrob Agents Chemother 18 1980 382 385
84. H.F. Chambers Penicillins and β-lactam inhibitors 7th ed. G.L. Mandell, J.E. Bennett, R. Dolin, Principles and practice of infectious diseases vol. 1 2010 Churchill Livingstone Elsevier Philadelphia, PA 309 322
85. M. Akova, Y. Yang, and D.M. Livermore Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed class I β-lactamases J Antimicrob Chemother 25 1990 199 208
86. M.L. Joly-Guillou, M. Kempf, J.D. Cavallo, M. Chomarat, L. Dubreuil, and J. Maugein Comparative in vitro activity of meropenem, imipenem and piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study BMC Infect Dis 10 2010 72
87. P.J. Turner Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results Diagn Microbiol Infect Dis 60 2008 185 192
88. P.R. Rhomberg, and R.N. Jones Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008) Diagn Microbiol Infect Dis 65 2009 414 426
89. A.C. Rodloff, R. Leclercq, E.A. Debbia, R. Canton, B.A. Oppenheim, and M.J. Dowzicky Comparative analysis of antimicrobial susceptibility among organisms from France, Germany, Italy, Spain and the UK as part of the Tigecycline Evaluation and Surveillance Trial Clin Microbiol Infect 14 2008 307 314
90. M.A. Pfaller, R.N. Jones, S.A. Marshall, S.L. Coffman, R.J. Hollis, and M.B. Edmond Inducible Amp C β-lactamase producing Gram-negative bacilli from blood stream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE) Diagn Microbiol Infect Dis 28 1997 211 219
91. J.A. Karlowsky, P.R. Lagace-Wiens, P.J. Simner, M.R. DeCorby, H.J. Adam, and A. Walkty Antimicrobial resistance in urinary tract pathogens in Canada from 2007 to 2009: CANWARD surveillance study Antimicrob Agents Chemother 55 2011 3169 3175
92. D.M. Livermore β-Lactamase-mediated resistance and opportunities for its control J Antimicrob Chemother 41 Suppl. D 1998 25 41
93. L.E. Stearne, D. van Boxtel, N. Lemmens, W.H. Goessens, J.W. Mouton, and I.C. Gyssens Comparative study of the effects of ceftizoxime, piperacillin, and piperacillin-tazobactam concentrations on antibacterial activity and selection of antibiotic-resistant mutants of Enterobacter cloacae and Bacteroides fragilis in vitro and in vivo in mixed-infection abscesses Antimicrob Agents Chemother 48 2004 1688 1698
94. F. Higashitani, K. Nishida, A. Hyodo, and M. Inoue Effects of tazobactam on the frequency of the emergence of resistant strains from Enterobacter cloacae, Citrobacter freundii, and Proteus vulgaris (β-lactamase derepressed mutants) J Antibiot (Tokyo) 48 1995 1027 1033
95. A. Gin, L. Dilay, J.A. Karlowsky, A. Walkty, E. Rubinstein, and G.G. Zhanel Piperacillin-tazobactam: a β-lactam/β-lactamase inhibitor combination Expert Rev Anti Infect Ther 5 2007 365 383
96. M. Marcos, A. Inurrieta, A. Soriano, J.A. Martinez, M. Almela, and F. Marco Effect of antimicrobial therapy on mortality in 377 episodes of Enterobacter spp. bacteraemia J Antimicrob Chemother 62 2008 397 403
97. M.J. Schwaber, C.S. Graham, B.E. Sands, H.S. Gold, and Y. Carmeli Treatment with a broad-spectrum cephalosporin versus piperacillin-tazobactam and the risk for isolation of broad-spectrum cephalosporin-resistant Enterobacter species Antimicrob Agents Chemother 47 2003 1882 1886
98. S.A. Zelenitsky, R.E. Ariano, and G.G. Zhanel Pharmacodynamics of empirical antibiotic monotherapies for an intensive care unit (ICU) population based on Canadian surveillance data J Antimicrob Chemother 66 2011 343 349
99. R.J. Yost, and D.M. Cappelletty The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) Study: a multicenter study Pharmacotherapy 31 2011 767 775
100. J. Turnidge Trimethoprim, co-trimoxazole and related agents L.M. Grayson, S. Crowe, J. McCarthy, J. Mills, J. Mouton, R. Norrby, al. et, Kucers' the use of antibiotics 6th ed. 2010 Hodder Arnold London, UK
101. M.E. Falagas, A.P. Grammatikos, and A. Michalopoulos Potential of old-generation antibiotics to address current need for new antibiotics Expert Rev Anti Infect Ther 6 2008 593 600
102. P.A. Masters, T.A. O'Bryan, J. Zurlo, D.Q. Miller, and N. Joshi Trimethoprim-sulfamethoxazole revisited Arch Intern Med 163 2003 402 410
103. P. Huovinen Resistance to trimethoprim-sulfamethoxazole Clin Infect Dis 32 2001 1608 1614
104. M.N. Al-Hasan, B.D. Lahr, J.E. Eckel-Passow, and L.M. Baddour Temporal trends in Enterobacter species bloodstream infection: a population-based study from 1998-2007 Clin Microbiol Infect 17 2010 539 545
105. J.M. Pogue, D. Marchaim, D. Kaye, and K.S. Kaye Revisiting "older" antimicrobials in the era of multidrug resistance Pharmacotherapy 31 2011 912 921
106. J.H. Darrell, L.P. Garrod, and P.M. Waterworth Trimethoprim: laboratory and clinical studies J Clin Pathol 21 1968 202 209
107. U. Schmidt, P. Sen, R. Kapila, and D.B. Louria Clinical evaluation of intravenous trimethoprim-sulfamethoxazole for serious infections Rev Infect Dis 4 1982 332 337
108. E.D. Ralph, and R.J. Behme Enterobacter meningitis - treatment complicated by emergence of mutants resistant to cefotaxime Scand J Infect Dis 19 1987 577 579
109. M.A. Wolff, C.L. Young, and R. Ramphal Antibiotic therapy for Enterobacter meningitis: a retrospective review of 13 episodes and review of the literature Clin Infect Dis 16 1993 772 777
110. R.E. Levitz, and R. Quintiliani Trimethoprim-sulfamethoxazole for bacterial meningitis Ann Intern Med 100 1984 881 890
111. E.E. Wang, and C.G. Prober Ventricular cerebrospinal fluid concentrations of trimethoprim-sulphamethoxazole J Antimicrob Chemother 11 1983 385 389
112. J.D.C. Yao, and R.C. Moellering Antibacterial agents 10th ed. J. Versalovic, K. Carroll, G. Funke, J.H. Jorgensen, M.L. Landry, D.W. Warnock, Manual of clinical microbiology vol. 1 2011 American Society of Microbiology Washington, DC 1061 1063
113. S.H. Zinner, and K.H. Mayer Sulfonamides and trimethoprim 7th ed. G.L. Mandell, J.E. Bennett, R. Dolin, Principles and practice of infectious diseases vol. 1 2010 Churchill Livingstone Elsevier Philadelphia, PA 475 486
114. J. Spicehandler, A.A. Pollock, M.S. Simberkoff, and J.J. Rahal Jr. Intravenous pharmacokinetics and in vitro bactericidal activity of trimethoprim-sulfamethoxazole Rev Infect Dis 4 1982 562 565
115. K.G. Sabel The treatment of meningitis in infants with co-trimoxazole administered parenterally Scand J Infect Dis Suppl 8 1976 86 90
116. D.R. Foster, and D.H. Rhoney Enterobacter meningitis: organism susceptibilities, antimicrobial therapy and related outcomes Surg Neurol 63 2005 533 537 [discussion 537]
117. N.P. Boye, and P. Gaustad Double-blind comparative study of ofloxacin (Hoe 280) and trimethoprim-sulfamethoxazole in the treatment of patients with acute exacerbations of chronic bronchitis and chronic obstructive lung disease Infection 19 Suppl. 7 1991 S388 S390
118. J.M. Ho, and D.N. Juurlink Considerations when prescribing trimethoprim-sulfamethoxazole CMAJ 183 2012 1851 1858
119. H. Heimpel, and A. Raghavachar Hematological side effects of co-trimoxazole Infection 15 Suppl. 5 1987 S248 S253
120. D.H. Lawson, and B.J. Paice Adverse reactions to trimethoprim- sulfamethoxazole Rev Infect Dis 4 1982 429 433
121. E.P. Perlmutter, D. Sweeney, G. Herskovits, and M. Kleiner Case report: severe hyperkalemia in a geriatric patient receiving standard doses of trimethoprim-sulfamethoxazole Am J Med Sci 311 1996 84 85
122. L.C. Faria, C.C. Resende, C.A. Couto, O.F. Couto, L.P. Fonseca, and T.C. Ferrari Severe and prolonged cholestasis caused by trimethoprim- sulfamethoxazole: a case report Clinics (Sao Paulo) 64 2009 71 74
123. M.J. Ilario, J.E. Ruiz, and C.A. Axiotis Acute fulminant hepatic failure in a woman treated with phenytoin and trimethoprim-sulfamethoxazole Arch Pathol Lab Med 124 2000 1800 1803
124. E. Karpman, and E.A. Kurzrock Adverse reactions of nitrofurantoin, trimethoprim and sulfamethoxazole in children J Urol 172 2004 448 453
125. E.L. Strevel, A. Kuper, and W.L. Gold Severe and protracted hypoglycaemia associated with co-trimoxazole use Lancet Infect Dis 6 2006 178 182
126. S. Walker, J. Norwood, C. Thornton, and D. Schaberg Trimethoprim- sulfamethoxazole associated rhabdomyolysis in a patient with AIDS: case report and review of the literature Am J Med Sci 331 2006 339 341
127. C. Capra, G.M. Monza, G. Meazza, and G. Ramella Trimethoprim- sulfamethoxazole-induced aseptic meningitis: case report and literature review Intensive Care Med 26 2000 212 214
128. M.P. Muller, D.C. Richardson, and S.L. Walmsley Trimethoprim- sulfamethoxazole induced aseptic meningitis in a renal transplant patient Clin Nephrol 55 2001 80 84
129. S. Weis, D. Karagulle, J. Kornhuber, and K. Bayerlein Cotrimoxazole-induced psychosis: a case report and review of literature Pharmacopsychiatry 39 2006 236 237
130. E.L. van der Veen, A.G. Schilder, T.K. Timmers, M.M. Rovers, A.C. Fluit, and M.J. Bonten Effect of long-term trimethoprim/sulfamethoxazole treatment on resistance and integron prevalence in the intestinal flora: a randomized, double-blind, placebo-controlled trial in children J Antimicrob Chemother 63 2009 1011 1016
131. T. Kelesidis, D.E. Karageorgopoulos, I. Kelesidis, and M.E. Falagas Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies J Antimicrob Chemother 62 2008 895 904
132. M.E. Falagas, P.I. Rafailidis, E. Ioannidou, V.G. Alexiou, D.K. Matthaiou, and D.E. Karageorgopoulos Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients Int J Antimicrob Agents 35 2010 194 199
133. M.E. Falagas, A.C. Kastoris, A.M. Kapaskelis, and D.E. Karageorgopoulos Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum β-lactamase producing, Enterobacteriaceae infections: a systematic review Lancet Infect Dis 10 2010 43 50
134. D.M. Livermore, M. Warner, S. Mushtaq, M. Doumith, J. Zhang, and N. Woodford What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline Int J Antimicrob Agents 37 2011 415 419
135. M.E. Falagas, K.P. Giannopoulou, G.N. Kokolakis, and P.I. Rafailidis Fosfomycin: use beyond urinary tract and gastrointestinal infections Clin Infect Dis 46 2008 1069 1077
136. G.E. Stein, and W.A. Craig Tigecycline: a critical analysis Clin Infect Dis 43 2006 518 524
137. D. Yahav, L. Farbman, L. Leibovici, and M. Paul Colistin: new lessons on an old antibiotic Clin Microbiol Infect 18 2011 18 29
138. E. Tasina, A.B. Haidich, S. Kokkali, and M. Arvanitidou Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis Lancet Infect Dis 11 2011 834 844
139. J. Li, R.L. Nation, J.D. Turnidge, R.W. Milne, K. Coulthard, and C.R. Rayner Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections Lancet Infect Dis 6 2006 589 601